Payment overview · 2025
General Payments
$61.28
3 reported records · 2 companies
Healthcare provider profile · identity verified
Brian J Bixler, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · SPRING HILL, FL · NPI 1326038613
Verified facts
What the public records show
CMS Open Payments records show Brian J Bixler, M.D. received $61.28 in general payments during 2025 across 3 reported records.
PFIZER INC. accounted for 68.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 3 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Trelegy Ellipta.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 65 claims for Trelegy Ellipta by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 70 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $41.70 | 68.0% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $19.58 | 31.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $61.28 | 3 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $41.70 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $41.70 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $19.58 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 70 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 65 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
65 | 16 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
70 | 15 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
13 | 13 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 388 | 102 |
| Amlodipine Besylate | Amlodipine Besylate | 364 | 94 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 356 | 93 |
| Levothyroxine Sodium | Levothyroxine Sodium | 331 | 89 |
| Losartan Potassium | Losartan Potassium | 311 | 86 |
| Lisinopril | Lisinopril | 305 | 87 |
| Pantoprazole Sodium | Pantoprazole Sodium | 283 | 80 |
| Simvastatin | Simvastatin | 271 | 77 |
| Metoprolol Succinate | Metoprolol Succinate | 223 | 61 |
| Alprazolam | Alprazolam | 217 | 58 |
| Montelukast Sodium | Montelukast Sodium | 217 | 61 |
| Tamsulosin Hcl | Tamsulosin Hcl | 203 | 65 |
| Famotidine | Famotidine | 202 | 63 |
| Omeprazole | Omeprazole | 201 | 55 |
| Hydrochlorothiazide | Hydrochlorothiazide | 186 | 52 |
| Tramadol Hcl | Tramadol Hcl | 184 | 61 |
| Gabapentin | Gabapentin | 179 | 46 |
| Metformin Hcl | Metformin Hcl | 176 | 51 |
| Clopidogrel | Clopidogrel Bisulfate | 163 | 48 |
| Fluticasone Propionate | Fluticasone Propionate | 147 | 61 |
| Temazepam | Temazepam | 147 | 34 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 139 | 55 |
| Trazodone Hcl | Trazodone Hcl | 127 | 38 |
| Metoprolol Tartrate | Metoprolol Tartrate | 126 | 41 |
| Alendronate Sodium | Alendronate Sodium | 115 | 34 |
| Furosemide | Furosemide | 113 | 35 |
| Glipizide | Glipizide | 111 | 31 |
| Escitalopram Oxalate | Escitalopram Oxalate | 97 | 34 |
| Sildenafil Citrate | Sildenafil Citrate | 94 | 20 |
| Potassium Chloride | Potassium Chloride | 91 | 26 |
| Testosterone Cypionate | Testosterone Cypionate | 91 | 13 |
| Pregabalin | Pregabalin | 88 | 21 |
| Baclofen | Baclofen | 87 | 24 |
| Allopurinol | Allopurinol | 85 | 20 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 81 | 32 |
| Pravastatin Sodium | Pravastatin Sodium | 79 | 22 |
| Prednisone | Prednisone | 79 | 61 |
| Carvedilol | Carvedilol | 76 | 21 |
| Eliquis | Apixaban | 70 | 15 |
| Buspirone Hcl | Buspirone Hcl | 68 | 16 |
| Duloxetine Hcl | Duloxetine Hcl | 68 | 22 |
| Citalopram Hbr | Citalopram Hydrobromide | 67 | 21 |
| Meloxicam | Meloxicam | 66 | 22 |
| Tizanidine Hcl | Tizanidine Hcl | 65 | 16 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 65 | 16 |
| Clonazepam | Clonazepam | 59 | 14 |
| Azithromycin | Azithromycin | 56 | 49 |
| Warfarin Sodium | Warfarin Sodium | 56 | 14 |
| Valsartan | Valsartan | 55 | 16 |
| Atenolol | Atenolol | 54 | 16 |
| Sertraline Hcl | Sertraline Hcl | 54 | 19 |
| Ezetimibe | Ezetimibe | 53 | 15 |
| Lovastatin | Lovastatin | 52 | 15 |
| Oxybutynin Chloride | Oxybutynin Chloride | 49 | 12 |
| Finasteride | Finasteride | 46 | 13 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 45 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 40 | 12 |
| Paroxetine Hcl | Paroxetine Hcl | 40 | suppressed |
| Lorazepam | Lorazepam | 39 | 14 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 38 | suppressed |
| Spironolactone | Spironolactone | 38 | 11 |
| Clonidine Hcl | Clonidine Hcl | 37 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 37 | 11 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 35 | 28 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 34 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 34 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 33 | 13 |
| Zolpidem Tartrate | Zolpidem Tartrate | 33 | 11 |
| Fenofibrate | Fenofibrate | 32 | suppressed |
| Gavilyte-G | Peg3350/Sod Sulf,bicarb,cl/Kcl | 32 | 32 |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 30 | suppressed |
| Januvia | Sitagliptin Phosphate | 29 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 29 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 28 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 28 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 28 | suppressed |
| Glipizide Er | Glipizide | 27 | suppressed |
| Mirtazapine | Mirtazapine | 27 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 27 | suppressed |
| Xarelto | Rivaroxaban | 27 | 12 |
| Amiodarone Hcl | Amiodarone Hcl | 26 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 26 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 26 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 25 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 24 | 18 |
| Hydralazine Hcl | Hydralazine Hcl | 23 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 22 | suppressed |
| Memantine Hcl | Memantine Hcl | 22 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 22 | suppressed |
| Synthroid | Levothyroxine Sodium | 22 | suppressed |
| Bupropion Xl | Bupropion Hcl | 21 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 21 | suppressed |
| Diazepam | Diazepam | 20 | 11 |
| Levetiracetam | Levetiracetam | 20 | suppressed |
| Ramipril | Ramipril | 20 | suppressed |
| Celecoxib | Celecoxib | 19 | suppressed |
| Estradiol | Estradiol | 17 | suppressed |
| Glimepiride | Glimepiride | 17 | suppressed |
| Topiramate | Topiramate | 17 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 16 | 13 |
| Benazepril Hcl | Benazepril Hcl | 16 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 15 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 15 | suppressed |
| Jardiance | Empagliflozin | 15 | suppressed |
| Ozempic | Semaglutide | 15 | suppressed |
| Cilostazol | Cilostazol | 14 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 14 | suppressed |
| Ketoconazole | Ketoconazole | 14 | suppressed |
| Nitroglycerin | Nitroglycerin | 14 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 13 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 13 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 13 | 13 |
| Fluoxetine Hcl | Fluoxetine Hcl | 12 | suppressed |
| Gemfibrozil | Gemfibrozil | 12 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 12 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 12 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 11 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 11 | suppressed |
| Fluconazole | Fluconazole | 11 | suppressed |
| Sucralfate | Sucralfate | 11 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 11 | suppressed |
| Verapamil Er | Verapamil Hcl | 11 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $61.28 · 3 records | PFIZER INC. | ELIQUIS, NURTEC ODT, TRELEGY ELLIPTA | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with GlaxoSmithKline, LLC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error